Differential psychopharmacotherapy in remission of recurrent depressive disorder
https://doi.org/10.30629/2618-6667-2015-67-32-41
Abstract
Background. The relevance of developing differentiated therapeutic strategies in remission of recurrent depressive disorder is based on an underestimation of the problem. Since there is alot of studies devoted to depressive episodes treatment, treatment modalities in remission are underinvestigated and limited by general recommendations about stabilizing and anti-recurrence treatment.The objective of the study was a naturalistic analysis of the methods of differential therapy of remissions in recurrent depression, depending on their clinical typology (symptomatic/partial or syndromal/ complete ) and residual symptoms genesis including psychopharmacological strategies investigation (i.a. combination therapy) during a period of maximum possible duration.Material and Methods. The sample included 186 patients (130 women, 56 men; mean age 45,8 ± 15,3 years) who have had at least three episodes of recurrent depression, separated by remissionslasting atleast 6 months.Results. The basic strategies of maintenance treatment in routine clinical practice, differentiated strategies offered drug treatment depending on the typology of remission and psychopathological characteristics of residual symptoms have been established on the basis of retro- and prospective study data.
References
1. Papakostas G.I., Fava M. Pharmacotherapy for depression and treatment-resistant depression. World Scientific Publishing Co. Pte. Ltd. 2010;728
2. Mindham, R.H., Howland C., Shepherd M. Continuation ther- apy with tricyclic antidepressants in depressive illness. The Lancet. 1972;2(7782):854-855
3. Mindham R.H., Howland C., Shepherd M. An evaluation of con- tinuation therapy with tricyclic antidepressants in depressive illness. Psychological Medicine. 1973;3(1):5-17
4. Stein M.K., Rickels K., Weise C.C. Maintenance therapy with amitriptyline: A controlled trial. Am. J. Psych. 1980. 137(3):370-371
5. Bialos D., Giller E., Jatlow P. et al. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am. J. Psych. 1982;139(3):325-329
6. Klerman G.L., Dimascio A., Weissman M. et al. Treatment of depression by drugs and psychotherapy. Am. J. Psych. 1974;131(2):186-191
7. Coppen A., Ghose K., Montgomery S. et al. Continuation therapy with amitriptyline in depression. B. J. Psych. 1978;133:28-33
8. Gilaberte I., Montejo A.L., de la Gandara J. et al. Fluoxetine in the prevention of depressive recurrences: A double-blind study. J. Clin. Psychopharmacol. 2001;21(4):417-424
9. Hochstrasser B., Isaksen P.M., Koponen H.et al. Prophylactic effect of citalopram in unipolar, recurrent depression: Pla- cebo-controlled study of maintenance therapy. B. J. Psych. 2001;178:304-310. DOI: 10.1192/bjp.178.4.304
10. Klysner R., Bent-Hansen J., Hansen H.L. et al. Efficacy of cit- alopram in the prevention of recurrent depression in elderly patients: Placebo-controlled study of maintenance therapy. B. J. Psych. 2002;181:29-35. DOI: 10.1192/bjp.181.1.29
11. Rapaport M.H., Bose A., Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J. Clin Psy- chiat. 2004;65(1):44-49. doi.org/10.4088/jcp.v65n0107
12. Emslie G.J., Heiligenstein J.H., Hoog S. L.et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: A double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry. 2004;43(11):1397-1405. doi.org/10.1016/s0084-3970(08)70051-3
13. Thase M.E., Nierenberg A.A., Keller M.B. et al. Efficacy of mir- tazapine for prevention of depressive relapse: Aplacebo-con- trolled double blind trial of recently remitted high-risk pa- tients. J. Clin. Psychiatry. 2001;62(10):782-788. doi.org/10.4088/jcp.v62n1006
14. Montgomery S.A., Kennedy S.H., Burrows G.D. et al. Absence of discontinuation symptoms with agomelatine and occur- rence of discontinuation symptoms with paroxetine: A ran- domized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 2004;19(5):271-380. http://dx.doi.org/10.1097/01.yic.0000137184.64610.c8
15. Frank E.D., Kupfer J., Perel J.M. et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch. Gen. Psychiatry. 1990;47:1093-1099. doi:10.1001/archpsyc.1990.01810240013002
16. McGrath P.J., Stewart J.W., Quitkin F.M. et al. Predictors of re- lapse in a prospective study of fluoxetine treatment of major depression. Am. J. Psych. 2006;163(9):1542-1548. http://dx.doi.org/10.1176/appi.ajp.163.9.1542
17. Kornstein S.G., Bose A., Li D. et al. Escitalopram mainte- nance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial. J. Clin. Psychiatry. 2006;67(11):1767-1775. http://dx.doi.org/10.4088/jcp.v67n1115
18. Reynolds C.F., Frank E., Perel J.M. et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: A randomized controlled trial in patients older than 59 years. JAMA. 1999; 281(1):39-45. doi:10.1001/jama.281.1.39
19. Kocsis J.H., Thase M.E., Trivedi M.H. et al. Prevention of re- current episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J. Clin. Psychia- try. 2007;68(7):1014-1023. http://dx.doi.org/10.4088/jcp.v68n0706
20. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. М. Медицинское информационное агентство. 2003
21. Nutt D.J., Davidson J.R., Gelenberg A.J., Higuchi T., Kanba S., Karamustafalio lu O., Papakostas G.I., Sakamoto K., Terao T., Zhang M. International consensus statement on major depres- sive disorder. J. Clin. Psychiatry. 2010;71(E1):e08. 10.4088/JCP.9058se1c.08gry
22. Dupuy J.M., Ostacher M.J., Huffman J., Perlis R.H., Nieren- berg A.A. A critical review of pharmacotherapy for major depressive disorder. Int. J. Neuropsychopharmacol. 2011 Nov;14(10):1417-1431. DOI: http://dx.doi.org/10.1017/S1461145711000083 1417-1431
23. Patkar A.A., Pae C.U. Atypical antipsychotic augmentation strat- egies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(1):29-37. doi: 10.1007/s40263-012-0031-0
24. Nierenberg A.A., Petersen T.J., Alpert J. E. Prevention of Re- lapse and Recurrence in Depression: The Role of Long-Term Pharmacotherapy and Psychotherapy. J. Clin. Psychiatry. 2003;64(15):13-17
25. Dombrovski A.Y., Cyranowski J.M., Mulsant B.H., Houck P.R., Buysse D.J., Andreescu C., Thase M.E. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? Depress Anxiety. 2008;25(12):1060-1066. DOI: 10.1002/da.20467
26. Israel J. The Impact of Residual Symptoms in Major Depres- sion. Pharmaceuticals. 2010;3:426-2440
27. Захарова К.В. Качество и стойкость ремиссии при применении фармакотерапии у больных с депрессивными расстройствами. Дис. … кан. мед. наук. М. 2008. 142 с. Доступно по: http://medical-diss.com/medicina/kachestvo- i-stoykost-remissii-pri-primenenii-farmakoterapii-u-bolnyh- s-depressivnymi-rasstroystvami Ссылка активна на 19.08.2015
28. Solomon D.A., Keller M.B., Leon A.C., Mueller T.I., Lavori P.W., Shea M.T. Multiple recurrences of major depressive disorder. Am. J. Psychiat. 2000;157:229-233. http://dx.doi.org/10.1176/appi.ajp.157.2.229
29. Judd L.L., Akiskal H.S. et al. A Prospective 12-Year Study of Subsyndromal and Syndromal Depressive Symptoms in Uni- polar Major Depressive Disorders. Arch. Gen. Psychiatry. 1998; 55(8):694-700. DOI: http://dx.doi.org/10.1016/S0006-3223(97)87817-1
30. McIntyre R., Fallu S.A., Konarski J.Z. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin. Ther. 2006;28(11):1882-1891. DOI: http://dx.doi.org/10.1016/j.clinthera.2006.11.007
31. Мосолов С.Н. Клиническое применение современных антидепрессантов. МИА. СПб, 1995
32. Canadian Psychiatric Association and Canadian Network for Mood and Anxiety Treatments. Clinical guidelines for the treatment of depressive. 2001
33. American Psychiatric Association (2010) (Eds: Gelen- berg A.J., Freeman M.P., Markowitz J.C., Rosenbaum J.F., Thase M.E., Trivedi M.H., Van Rhoads R.S.). Practice Guide- lines for the Treatment of Patients with Major Depressive Disorder, 3rd Edition
34. Australian and New Zealand clinical practice guidelines for the treatment of depression. 2004
35. Городничев А.В. Достижение ремиссии как основная цель длительной терапии рекуррентного депрессивного расстройства (анализ данных литературы и результатов оригинального сравнительного рандомизированного исследования антидепрессантов разных поколений), Современная терапия психических расстройств. 2009;1:5-10
36. Смулевич А.Б., Андрющенко А.В., Романов Д.В., Захарова Н.В. Ремиссии при аффективных заболеваниях: эпидемиология, психопатология, клинический и социальный прогноз, вторичная профилактика. Журн. неврол. и психиатр. им. С.С. Корсакова. 2014;114(3):4-13. 41
37. Smulevich A.B. Andryushchenko A.V., Romanov D.V., Zakharo- va N.V. Remission of recurrent unipolar depression: clinical types and impact of personality disorders. European Neuro- psychopharmacology. Оctober 2014;24(2):405. DOI: http://dx.doi.org/10.1016/S0924-977X(14)70645-5
38. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., La- vori P.W., Rush A.J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depres- sive disorder: remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry. 1991;48:851-855
39. Karp J.F., Buysse D.J., Houck P.R. et al. Relationship of Variability in Residual Symptoms with Recurrence of Major Depressive Disorder During Maintenance Treatment. Am. J. Psych. 2004;161:1877-1888
40. von Leuter H. Phasen uber dauern der Pers nlichkeits wandel und persistierende Symptome bei der endogenen Depres- sion. Das Depressivе Syndrome. Uerban & Schwаrzenberg. 1968:127-152
41. Шостакович Б.В. Расстройства личности (психопатии) в судебно-психиатрической практике. М., 2006
42. Ladee G.A. Hypochondrische Syndromes. Amsterdam-Lon- don-NY. 1966
43. Mueller T.I., Leon A.C., Keller M.B., Solomon D.A. et al. Re- currence After Recovery From Major Depressive Disorder During 15 Years of Observational Follow-Up. Am. J. Psych. 1999;156:1000-1006. PMID: 10401442 [PubMed - indexed for MEDLINE]
44. Bockting C.L. (DELTA study group: M.C. ten Doesschate, J. Spi- jker, P. Spinhoven, M.W. Koeter, A.H. Schene) Continuation and maintenance use of antidepressants in recurrent depres- sion. Psychother. Psychosom. 2008;77(1):17-26
45. Горбунова А.А., Колюцкая Е.В. Паническое расстройство и аффективная патология (аспекты коморбидности). Журн. неврол. и психиатр. им. С С. Корсакова. 2014; 10:9-13
46. Zajecka J. Treating Depression to Remission. J. Clin. Psychi- atry. 2003;64(15):7-12
Review
For citations:
Zakharova N. Differential psychopharmacotherapy in remission of recurrent depressive disorder. Psychiatry (Moscow) (Psikhiatriya). 2015;(3):32-41. (In Russ.) https://doi.org/10.30629/2618-6667-2015-67-32-41
Views:
562
Email this article 
